Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

• Published in: Clinical cancer research 2006-04, Vol.12 (7), p.2264-2271
• Main Authors: SARKARIA, Jann N, CARLSON, Brett L, JAMES, C. David, SCHROEDER, Mark A, GROGAN, Patrick, BROWN, Paul D, GIANNINI, Caterina, BALLMAN, Karla V, KITANGE, Gaspar J, GUHA, Abjahit, PANDITA, Ajay
• Format: Article
• Language: English
• Subjects: Adult; Aged; Amplification; Animals; Antineoplastic agents; Biological and medical sciences; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; EGFR; Erlotinib Hydrochloride; Female; Gene Amplification; Glioblastoma; Glioblastoma - drug therapy; Glioblastoma - metabolism; Glioblastoma - radiotherapy; Humans; Male; Medical sciences; Mice; Mice, Nude; Middle Aged; Neurology; Pharmacology. Drug treatments; Quinazolines - pharmacology; Radiation; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; Survival Rate; Transplantation, Heterologous; Tumors of the nervous system. Phacomatoses; Xenograft Model Antitumor Assays
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-05-2510

Purpose: The influence of epidermal growth factor receptor ( EGFR ) amplification on glioblastoma patient prognosis following definitive radiotherapy has been extensively investigated in clinical studies, and yet the relationship between EGFR status and radiation response remains unclear. The intent of the current study was to address this relationship using several EGFR-amplified glioblastoma xenografts in an orthotopic athymic mouse model. Experimental Design: We examined the effect of radiation on the survival of nude mice with intracranial xenografts derived from 13 distinct patient tumors, 7 of which have amplified EGFR. Mice with established intracranial tumors were randomized to sham treatment or 12-Gy radiation in six fractions delivered over 12 days. Results: For six of the xenografts, radiation of mice with intracranial tumor significantly extended survival, and four of these xenografts had EGFR amplification. For seven other xenografts, radiation treatment did not significantly extend survival, and three of these, including GBM12, had EGFR amplification. Similar to EGFR, the tumor genetic status of p53 or PTEN did not show preferential association with radiation-sensitive or radiation-resistant xenografts whereas hyperphosphorylation of Akt on Ser 473 was associated with increased radioresistance. To specifically investigate whether inhibition of EGFR kinase activity influences radiation response, we examined combined radiation and EGFR inhibitor treatment in mice with intracranial GBM12. The combination of oral erlotinib administered concurrently with radiation resulted only in additive survival benefit relative to either agent alone. Conclusions: Our results indicate that EGFR amplification, as a biomarker, is not singularly predictive of glioblastoma response to radiation therapy, nor does the inhibition of EGFR enhance the intrinsic radiation responsiveness of glioblastoma tumors. However, efficacious EGFR inhibitor and radiation monotherapy regimens can be used in combination to achieve additive antitumor effect against a subset of glioblastoma.